The research began with a deliberately focused starting point: lipid metabolism. Metabolic dysfunction sits at the heart of diabetes, and bioactive lipid mediators are known to shape skin inflammation and immunity, so the team reasoned that genes tied to lipid handling might yield clues about why diabetic wounds fail to close. Using public gene expression data deposited in the Gene Expression Omnibus under accession numbers GSE80178, GSE68183, GSE134431, GSE199939 and GSE223964, the investigators first identified differentially expressed genes between diabetic ulcer samples and non-ulcer controls, then intersected those changes with curated lipid metabolism-related gene sets drawn from the Molecular Signatures Database.

From that intersection, the researchers deployed a random forest machine learning model, an ensemble method that builds many decision trees on random subsets of the data and votes on the most informative features. The algorithm whittled the candidate list down to a compact panel of ten genes: ANGPTL4, BNIP3, EEF2K, EIF4EBP1, KLHDC1, KLK10, KLK8, NFIX, QSOX1 and S100A8. When the model’s performance was evaluated with receiver operating characteristic analysis, the ten-gene panel showed strong discrimination between ulcer and non-ulcer tissue, and its expression patterns proved reproducible across external validation cohorts that the model had never seen during training.

Each member of the panel carries biological weight in the context of wound repair. ANGPTL4, an angiopoietin-like protein, has been implicated in fibrotic progression in diabetic kidney disease and acts as a regulator of lipid metabolism during systemic inflammation. BNIP3 is a mitochondrial receptor that triggers mitophagy, the selective disposal of damaged mitochondria, a process increasingly recognized as a checkpoint of immune function. EEF2K and EIF4EBP1 sit on pathways governing protein synthesis and the mechanistic target of rapamycin complex 1, a nutrient-sensing hub. KLK8 and KLK10 belong to the kallikrein family of secreted proteases, NFIX is a transcription factor, QSOX1 participates in extracellular matrix maturation through hydrogen peroxide production, and S100A8 is a well-characterized alarmin released during inflammatory responses.

To understand what the signature means immunologically, the team applied single-sample gene set enrichment analysis, gene set enrichment analysis, and gene set variation analysis to the transcriptomic data. These techniques estimate the activity of predefined biological pathways within each individual sample rather than averaging across groups. The analyses linked the ten-gene panel to infiltration by T helper 17 cells, a pro-inflammatory CD4 T cell subset defined by production of interleukin 17A, and to interleukin receptor activity. The connection is biologically plausible: previous work has shown that suppressing Th17 cell differentiation can promote diabetic chronic wound healing, and pro-inflammatory cytokines such as interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha are established contributors to impaired repair in diabetic skin.

Single-cell RNA sequencing added a spatial and cellular dimension to the findings. By profiling gene expression in individual cells recovered from wound tissue, the researchers localized the panel genes to distinct wound-associated cell populations, showing that the signature is not a diffuse tissue-level signal but a composite of specific cell types responding to the diabetic wound environment. This cell-specific attribution matters for interpretation, because a gene that appears elevated in bulk tissue may reflect a shift in cellular composition rather than a change in per-cell expression, and disentangling the two is essential for choosing the right therapeutic target.

The computational work was then stress-tested in living animals. The team induced diabetes in C57BL/6 mice with streptozotocin, a chemical that destroys insulin-producing beta cells, and created standardized wounds whose closure was tracked by serial imaging. Diabetic mice exhibited delayed wound closure and greater residual wound widths than non-diabetic control animals, reproducing the clinical phenotype the gene panel is meant to explain. Hematoxylin and eosin staining of wound sections allowed the researchers to assess tissue architecture, while quantitative real-time polymerase chain reaction measured transcript levels of representative genes, enzyme-linked immunosorbent assays quantified secreted protein markers, and western blotting confirmed changes at the protein level. Critically, the transcript and protein assays showed concordant changes, meaning the RNA-level signature translated into measurable molecular differences in the wounded tissue.

Beyond diagnosis, the study explored therapeutic angles through drug-gene interaction analysis using the Drug Gene Interaction Database, which catalogs known relationships between genes and pharmacological compounds. This step flags whether any of the ten biomarkers are already druggable or targeted by existing agents, offering a shortcut from biomarker discovery to repurposing opportunities. The authors also performed single-gene pathway analyses for each hub gene, mapping individual genes onto Kyoto Encyclopedia of Genes and Genomes pathways, and compared pathway activity between high- and low-expression groups for every member of the panel, revealing how each gene’s expression level reshapes the surrounding signaling landscape.

The significance of the work lies in its integration. Biomarker studies often rely on a single dataset and a single method, leaving results vulnerable to batch effects and cohort-specific quirks. By combining differential expression, machine learning feature selection, multiple enrichment frameworks, single-cell resolution, external validation, and an animal model with orthogonal protein-level confirmation, the researchers built a chain of evidence in which each link compensates for the weaknesses of the others. The result is a candidate signature that behaves consistently across human cohorts and mouse wounds, and that points toward a coherent biological story in which lipid metabolic stress, defective mitophagy, and Th17-driven inflammation converge to keep diabetic ulcers open.

The authors are careful to note the limits of the work. The panel remains a candidate biomarker set, and further validation in larger human cohorts is required before any clinical application, whether as a diagnostic test to stratify patients at risk of non-healing or as a guide to anti-inflammatory therapy. Diabetic foot ulcers impose a heavy and unequal burden globally, and a molecular yardstick that captures the immune and metabolic state of a wound could eventually help clinicians decide which lesions need aggressive intervention and which are likely to progress toward closure. For now, the ten-gene panel offers researchers a concrete molecular handle on one of diabetes most stubborn complications, and a template for how machine learning and classical wet-lab validation can be stitched together to interrogate complex disease tissue.

Subject of Research: Identification of candidate biomarkers and immune features in diabetic ulcers through integrative transcriptomic and machine learning analysis

Article Title: Integrative transcriptomic and machine learning analysis identifies candidate biomarkers and immune features in diabetic ulcers

Article References: Jiang, Y., Cai, Y., Liu, Q., Jiang, J., Shen, F., Zhang, Y., Fei, X., Kuai, L., Zhang, Z., Luo, Y., Song, J., Ma, X., Li, B., Ma, X., & Ru, Y. (2026). Integrative transcriptomic and machine learning analysis identifies candidate biomarkers and immune features in diabetic ulcers. Molecular Biology Reports, 53(1), Article 1669. https://doi.org/10.1007/s11033-026-12862-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12862-z

Keywords: diabetic ulcers, biomarkers, machine learning, transcriptomics, lipid metabolism, Th17 cells, single-cell RNA sequencing, wound healing, random forest, immune microenvironment, ANGPTL4, S100A8

The scale of the problem is staggering. Diabetes affected about 463 million people, roughly 9.3 percent of the global population, as of 2019, and chronic hyperglycemia gradually damages nerves and blood vessels throughout the body. When peripheral nerves deteriorate, patients lose protective sensation in their feet; when blood vessels narrow, tissues are starved of oxygen and nutrients. The review notes that neuropathy is the primary cause of diabetic ulcers, with 18.7 percent of cases classified as hypoxic and 34.2 percent as neuro-hypoxic. Add in impaired immune responses, stem cell dysfunction, growth factor imbalances, and a heightened susceptibility to infection by organisms such as Staphylococcus aureus—including methicillin-resistant strains—and the result is a wound environment that stubbornly resists healing. Current treatments, from offloading pressure and wound care to growth factors, stem cell therapy, and bioengineered skin substitutes, often fail to address every stage of the healing cascade: coagulation, inflammation, proliferation, and remodelling.

Thymosin beta 4 is a compact, naturally occurring protein of just 43 amino acids, with a molecular weight of 4.9 kilodaltons, originally isolated from bovine thymus. It is highly conserved and water-soluble, found in nearly every tissue and cell type except erythrocytes. Upon injury, platelets, natural killer cells, and other cells release Tβ4, which protects against further damage, reduces programmed cell death, curbs microbial proliferation, and dampens inflammation. Mechanistically, the peptide interacts with actin to drive cell movement, promotes the differentiation of progenitor cells, epithelial cells, and keratinocytes, and stimulates the formation of new blood vessels. Crucially, it also reduces the accumulation of myofibroblasts at wound sites, which translates into less scar tissue and fibrosis. In diabetic models, Tβ4 treatment has improved motor and sensory nerve conduction velocities, accelerated re-epithelialization, increased vascularization, and enhanced cell viability through pathways including PI3K/AKT and vascular endothelial growth factor signalling.

The review details how Tβ4 manipulates several key signalling cascades relevant to diabetic wounds. It prevents the transcription factor NF-κB from entering the cell nucleus, thereby lowering production of pro-inflammatory molecules such as interleukin-8. It bolsters antioxidant defences by enhancing superoxide dismutase and catalase activity while suppressing tumor necrosis factor alpha and interleukin-6, partly through modulation of the NADPH oxidase system and activation of the Nrf2 pathway. It increases Angiopoietin-1 expression and stabilizes newly formed blood vessels via the Ang1/Tie2 axis, and it activates Wnt/β-catenin signalling to enhance endothelial cell migration, proliferation, and angiogenesis. Through PI3K/AKT signalling, Tβ4 stimulates endothelial nitric oxide synthase, boosting nitric oxide production, vasodilation, and blood flow to healing tissue. Studies in human umbilical vein endothelial cells have also shown that Tβ4 pretreatment reduces harmful reactive oxygen species, restores VEGF expression, and activates insulin-like growth factor 1 signalling, protecting cells from high-glucose toxicity.

Selenium, for its part, is an essential trace element with potent antioxidant, antibacterial, and anti-inflammatory properties. As a coenzyme component of glutathione peroxidase, it neutralizes reactive oxygen species, reduces lipid peroxidation, and lowers neutrophil infiltration into wounds—effects reflected in decreased malondialdehyde and myeloperoxidase levels. Selenium supplementation has been shown to restore extracellular superoxide dismutase and VEGF levels within diabetic ulcers, both essential for angiogenesis and oxidative stress control. Novel delivery platforms are extending these effects: selenium-treated exosomes derived from mesenchymal stem cells have reduced inflammation and enhanced pro-angiogenic activity in endothelial cells, while chitosan-nano selenium biofilms have improved full-thickness wound regeneration in diabetic models. Organo-selenium bandages have even been shown to inhibit bacterial biofilm formation, directly tackling one of the most stubborn obstacles to healing infected ulcers.

The molecular logic of the proposed combination is where the review becomes particularly compelling. Both agents converge on the same central pathways. In the PI3K/AKT cascade, Tβ4 activates signalling to promote cell survival and migration, while selenium enhances Akt phosphorylation through selenoprotein-mediated redox regulation—together amplifying anti-apoptotic and pro-survival signals. On the inflammatory front, selenium-containing glutathione peroxidases suppress NF-κB activation through their antioxidant activity, complementing Tβ4’s direct inhibition of NF-κB nuclear translocation, potentially producing a stronger anti-inflammatory effect in the wound environment than either agent could achieve alone. In the JAK/STAT pathway, Tβ4 modulates STAT3 activation to influence cell proliferation and migration, while selenium affects JAK2/STAT3 signalling through redox-sensitive mechanisms. Both also touch the Wnt/β-catenin pathway, suggesting combined effects on stem cell activation, tissue regeneration, and wound re-epithelialization.

The synergy extends beyond pathway overlap. Tβ4 upregulates VEGF expression and promotes endothelial cell differentiation, while selenium protects those newly formed vessels from oxidative damage by activating Nrf2. Selenium’s ability to modulate matrix metalloproteinases may complement Tβ4’s regulation of actin cytoskeleton reorganization, potentially improving wound contraction and remodelling. The review also highlights metabolic benefits: Tβ4 treatment lowers total cholesterol, triglycerides, and LDL cholesterol while raising HDL cholesterol, and both agents have been linked to improved insulin sensitivity. Selenium supplementation in patients with type 2 diabetes has reduced oxidative stress markers and improved glucose homeostasis and lipid profiles, meaning the combination might address not just the wound but the underlying diabetic pathophysiology that keeps wounds from closing.

Safety data offer cautious encouragement. A phase 1 study of recombinant human thymosin beta 4 (NL005) in healthy volunteers found adverse events were generally mild to moderate, with no serious toxicities and dose-proportional plasma concentrations. Topical Tβ4 in patients with venous stasis ulcers was well tolerated at all doses, with a 0.03 percent concentration showing the highest healing rate and a significantly reduced median healing time compared with placebo. But selenium is a double-edged sword: the review notes that blood levels exceeding roughly 140 nanograms per millilitre are extremely toxic to humans, causing selenosis and potential neurological damage, and excessive doses can paradoxically elevate pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha, slowing healing. Individual variability in response to Tβ4 and concerns about long-term effects also warrant further study.

The authors are careful to stress that the synergy between Tβ4 and selenium remains theoretical; no study has yet directly tested the combination in diabetic ulcers. They propose a research roadmap beginning with in vitro experiments combining the two agents in cell cultures to assess effects on fibroblast migration, keratinocyte proliferation, and inflammatory markers, followed by animal studies in diabetic wound models measuring wound closure time, angiogenesis, inflammation resolution, and infection control. Only then would well-structured clinical trials establish safety, efficacy, and optimal dosing ratios in patients with chronic diabetic ulcers. Key challenges include defining the optimal Tβ4-to-selenium ratio, managing selenium toxicity—particularly in patients with compromised renal function—and developing delivery systems that maintain the stability and bioavailability of both compounds at the wound site. If those hurdles can be cleared, the reviewers argue, the combination could reduce amputation rates, accelerate healing, and ease the enormous economic burden of diabetic foot ulcers, offering a genuinely integrated attack on a wound that has defeated conventional medicine for decades.

Subject of Research: Combined therapeutic effects of thymosin beta 4 and selenium on diabetic ulcer wound healing

Article Title: The combined impact of thymosin beta 4 and selenium on diabetic ulcers: a comprehensive review

Article References: Srinivasan, K., Sureshkumar, R., Nellore, J., Muthaiah, B., Selvan Christyraj, J. R. S., & Chandrasekaran, V. N. (2025). The combined impact of thymosin beta 4 and selenium on diabetic ulcers: a comprehensive review. Discover Biotechnology, 2(1), Article 11. https://doi.org/10.1007/s44340-025-00015-0

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00015-0

Keywords: thymosin beta 4, selenium, diabetic ulcers, wound healing, angiogenesis, oxidative stress, NF-kB, PI3K/AKT pathway, inflammation, insulin sensitivity, diabetic neuropathy, nanoparticles

The central argument of the review is that modern wound care needs materials that do more than cover. Biomaterial-based polymeric patches are designed to combine three functions in a single platform: structural support for fragile new tissue, controlled delivery of therapeutic agents, and direct regenerative activity. Achieving that combination requires careful attention to a set of design determinants that the authors lay out systematically. Biocompatibility ensures the material does not provoke an immune attack; biodegradability allows the patch to be absorbed as the wound heals rather than requiring painful removal; mechanical integrity keeps the patch intact under the stresses of movement; and the polymer’s origin, whether natural or synthetic, shapes degradation rates, cell interactions, and regulatory pathways. Increasingly, researchers are also incorporating bioactive secondary metabolites, plant-derived compounds and other natural molecules with documented anti-inflammatory, antimicrobial, and pro-regenerative effects, to give the patch genuine pharmacological punch.

Among the most versatile platforms are hydrogels, three-dimensional polymer networks that can hold large quantities of water while remaining soft and tissue-like. Hydrogels maintain the moist environment that wound healing requires, and their crosslinked structure can be tuned to release drugs over hours or days. The review highlights natural polymer hydrogels based on alginate, chitosan, and carboxymethyl cellulose, which have shown anti-inflammatory and healing-accelerating effects in both in vitro and in vivo studies. Photo-crosslinkable gelatin methacryloyl hydrogels allow researchers to pattern the material with light, creating scaffolds that mimic the extracellular matrix. Injectable hydrogel formulations are pushing further, offering targeted control of oxidative stress, one of the key biochemical culprits that keeps diabetic wounds locked in a chronic, non-healing state. Conductive hydrogel patches add yet another dimension, using bioelectric stimulation to encourage cell migration and regeneration while doubling as wearable sensors.

Electrospun nanofiber scaffolds represent a second major architectural family. By drawing polymer solutions through an electric field, manufacturers can produce mats of fibers with diameters in the nanometer range, closely resembling the fibrous architecture of the natural extracellular matrix. This biomimetic topology encourages cells to attach, proliferate, and migrate across the wound bed. The review cites work on polycaprolactone-zinc scaffolds coated with fibroblast-derived extracellular matrix, which enhanced cell proliferation, migration, and fibroblast differentiation, and on radially oriented berberine-loaded PHBV nanofiber dressings designed to accelerate diabetic wound closure. Electrospun dressings loaded with carbon quantum dots and citrate have demonstrated improved antibacterial efficiency, and the technology has begun to appear in real-world clinical evaluation, with commercial systems such as Spincare being assessed for practical wound coverage.

Microneedle arrays are perhaps the most visually striking of the new architectures. These patches studded with microscopic needles, often tens to hundreds of micrometers tall, can painlessly penetrate the tough, dead surface layer of a chronic wound and deposit drugs, growth factors, or biomolecules directly into viable tissue below. The review describes bioinspired wearable polymer microneedle patches developed specifically for diabetic wound therapy, as well as multifunctional designs such as a kangfuxin-chitosan-fucoidan complex patch that enabled full-thickness wound healing in preclinical models, and ROS-scavenging microneedle patches that mop up the reactive oxygen species implicated in chronic inflammation. Because microneedles can be engineered from dissolving or biodegradable polymers, they can leave no sharps waste and release their payload as they dissolve, combining delivery, mechanical debridement of the wound surface, and safety in one device.

Multilayered composite dressings take a different approach to the same problem: rather than one material doing everything, they assign each layer a job. A typical bilayer or trilayer patch might feature a tough, bacteria-blocking outer film, a middle layer that stores and slowly releases therapeutics, and a soft, adhesive inner layer that conforms to the wound. The review points to examples including gelatin-chitosan bilayer patches loaded with medicinal plant extracts, tri-layer dressings combining zinc oxide nanoparticles with insulin-like growth factor 1 for full-thickness skin injuries, and pollen-integrated hydrogel patches with hierarchical structures that release active compounds in a spatio-temporally controlled fashion. This architectural sophistication mirrors the layered structure of skin itself and allows formulators to reconcile requirements, such as moisture retention and mechanical strength, that would otherwise conflict within a single material.

The most futuristic entries in the review are the smart, responsive patches that merge wound care with diagnostics. Hydrogel-based electronic-skin patches have been demonstrated that both accelerate healing and monitor the state of the wound in real time. Conducting polymer arrays with multiplex sensing and drug-delivery capabilities form the basis of next-generation smart bandages, while a negative-pressure smart patch has been reported that can both sense wound conditions and apply therapy on demand. Wearable platforms built on hydrogels are being designed to track biomarkers such as pH, temperature, uric acid, and moisture, parameters that correlate with infection and healing progress, and to trigger therapeutic release only when needed. The authors note that artificial intelligence is beginning to enter this space, with machine-learning approaches proposed for interpreting sensor data and personalizing treatment, turning the humble dressing into a closed-loop therapeutic system.

Underpinning all of these architectures is a growing appreciation of wound biology. The review situates material design within the cellular choreography of repair: the inflammatory phase dominated by macrophages whose plasticity determines whether healing proceeds or stalls, the proliferative phase in which fibroblasts lay down new matrix and new blood vessels form, and the remodeling phase that determines final scar quality. In diabetic and chronic wounds, elevated oxidative stress, persistent infection, and dysregulated inflammation derail this sequence. Bioactive metabolites from plants, marine peptides, and even microbial sources are being explored as natural modulators that can nudge the wound environment back toward regeneration, and polymer chemists are learning to embed these molecules without destroying their activity.

Yet the review’s most sobering contribution is its assessment of translation. Despite an impressive laboratory literature, the number of advanced polymeric patches that have reached routine clinical use remains small. The authors identify a cluster of recurring barriers: manufacturing scalability, since processes like electrospinning and microneedle molding are difficult to reproduce at industrial scale with consistent quality; product standardization, because natural polymers vary batch to batch; regulatory approval pathways that were not designed for combination products blending drug, device, and biological functions; cost-effectiveness in health systems already strained by chronic wound care; and, above all, the scarcity of large-scale clinical validation. Registered clinical trials of advanced patches, including nitric oxide-releasing patches for diabetic foot ulcers and hemostatic patches for surgery, exist but remain limited in number and scope relative to the volume of preclinical publications. The review also flags the poor quality of many animal studies and calls for better standardized reporting, citing newly proposed guidelines for wound-healing research.

The overall picture that emerges is of a field at an inflection point. The material science has arguably outpaced the clinical science: researchers can now build patches that sense, deliver, stimulate, and regenerate, but the pathway from elegant prototype to approved, affordable, widely available product remains bottlenecked by economics, regulation, and evidence. By integrating advances in material design with an honest appraisal of translational and clinical considerations, Nandi and colleagues offer a framework intended to help the next generation of patches cross that gap. For the millions of patients whose wounds will not heal, the promise is real, but so, the review makes clear, is the distance still to travel.

Subject of Research: Bioactive polymeric patches and advanced dressing architectures for chronic wound healing and their translational challenges

Article Title: Next-generation bioactive polymeric patches for chronic wound healing: from advanced architectures to translational challenges

Article References: Nandi, A., Ahmed, R. K., & Chakrabarti, S. (2026). Next-generation bioactive polymeric patches for chronic wound healing: from advanced architectures to translational challenges. Polymer Bulletin, 83(12), Article 643. https://doi.org/10.1007/s00289-026-06697-8

Image Credits: AI Generated

DOI: 10.1007/s00289-026-06697-8

Keywords: chronic wounds, wound healing, biomaterials, hydrogels, electrospun nanofibers, microneedles, smart dressings, drug delivery, tissue regeneration, polymers, diabetic ulcers, clinical translation